IDEXX Laboratories (FRA:IX1) Total Stockholders Equity: €1,400 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:IX1 IDEXX Laboratories Inc FRA:IX1
96 GF Score
Price €505.80
GF Value €540.93
Valuation Fairly Valued
View Full Analysis

What is IDEXX Laboratories Total Stockholders Equity?

IDEXX Laboratories FRA:IX1 -0.75% 96 Total Stockholders Equity is €1,400 Mil as of Jun. 2026. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €540.93 (Fairly Valued).

IDEXX Laboratories's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €1,400 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. IDEXX Laboratories's Book Value per Share for the quarter that ended in Jun. 2026 was €17.75. The ratio of a company's debt over equity can be used to measure how leveraged this company is. IDEXX Laboratories's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.68.

IDEXX Laboratories  (FRA:IX1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

IDEXX Laboratories's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1399.715-0)/78.874
=17.75

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

IDEXX Laboratories's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(603.88 + 347.519) / 1399.715
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Total Stockholders Equity Related Terms

IDEXX Laboratories Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Total Stockholders Equity Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 610.64 574.65 1,361.31 1,523.52 1,371.00

IDEXX Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,264.80 1,330.13 1,371.00 1,346.03 1,399.72
FRA:IX1
96GF Score
IDEXX Laboratories Inc FRA:IX1
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €1,400 Mil mean?
IDEXX Laboratories (FRA:IX1) has a Total Stockholders Equity of €1,400 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Total Stockholders Equity too high?
IDEXX Laboratories' current Total Stockholders Equity is €1,400 Mil. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Total Stockholders Equity compare to A and NTRA?
IDEXX Laboratories' Total Stockholders Equity of €1,400 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Diagnostics & Research company?
A good Total Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for IDEXX Laboratories and its competitors. IDEXX Laboratories's current Total Stockholders Equity is €1,400 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Fairly Valued. The stock's GF Value™ is €540.93, compared to a current price of €505.80 — trading 6.5% below its estimated fair value. The current Total Stockholders Equity is €1,400 Mil. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current Total Stockholders Equity is €1,400 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of €505.80 is trading 6.5% below its estimated GF Value™ of €540.93. GuruFocus considers IDEXX Laboratories to be Fairly Valued.

Key valuation signals for FRA:IX1:

  • Total Stockholders Equity: €1,400 Mil
  • GF Value™: €540.93 vs. price of €505.80 (6.5% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score

Get the complete analysis for FRA:IX1

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€505.80
Price
€540.93
GF Value